Inquiry Basket
Loading ......
The central nervous system depends on the blood-brain barrier (BBB) as an essential physiological defense system. The blood-brain barrier maintains brain internal stability through selective regulation of substance transfer between blood and brain tissue. Research into the BBB structure and its transporters functions is essential for foundational neuroscience studies and creating treatments for central nervous system disorders.
Figure 1. Mechanisms of drug transport across blood-brain barrier (BBB). (Sources: Lee MR, et al. 2019)
Physical Barrier
Tight junctions formed by brain microvascular endothelial cells establish the primary physical barrier of the BBB. Tight junctions generate an uninterrupted barrier that stops large molecules and dangerous substances from infiltrating brain tissue. The architecture functions to shield the brain's sensitive neural environment from harmful toxins and large molecular disturbances.
Biochemical Barrier
The endothelial cell membrane houses multiple transporters and receptors to manage substance transfer. Glucose transporter GLUT1 along with amino acid transporters and ion channels serve as examples of these transport mechanisms. Brain transporters enable essential nutrient absorption while maintaining ionic balance which allows the brain to retain its energy needs and preserve physiological function through proper ionic conditions.
Immunological Barrier
The blood-brain barrier's immunological defense relies on the support provided by astrocytes and pericytes. These cells produce and control cytokines which work as protective agents against immune system damage to brain tissue. They preserve neural stability and health by controlling immune responses within the brain microenvironment.
Passive Diffusion
Cell membranes allow lipid - soluble small molecules like oxygen and carbon dioxide to pass through by simple diffusion. A brain receives enough oxygen through this straightforward transport method to perform aerobic respiration and remove carbon dioxide waste.
Active Transport
Transport proteins require energy to move nutrients including glucose and amino acids through the blood-brain barrier into brain cells. The brain requires this process because it demands substantial energy and essential building blocks for both normal neural function and repair mechanisms. GLUT1 functions as the primary glucose transporter that preserves high glucose levels in brain tissue.
Efflux Transport
The brain tissue utilizes efflux transporters including P - glycoprotein (P - gp) and multi - drug resistance proteins (MRP) to eliminate toxic substances. These substances form protective barriers to stop toxins and drugs from accumulating in brain tissue.
Receptor - Mediated Transport
The brain tissue allows molecules like insulin and transferrin to enter through a process known as receptor-mediated endocytosis. The brain makes use of selective uptake mechanisms to absorb essential signaling molecules along with nutrients which sustain its normal development and functioning.
Glucose Transporters (GLUTs)
GLUT1 serves as the primary glucose transporter of the BBB. GLUT1 provides an uninterrupted glucose supply which meets the brain's significant energy requirements because glucose serves as its primary energy source.
Amino Acid Transporters
The transport functions of Systems L and N involve neutral and basic amino acids respectively. Proteins built from amino acids support neural development and repair while also helping form neurotransmitters.
Ion Channels and Transporters
The Na⁺/K⁺ - ATPase and monocarboxylate transporters (MCT) maintain ion balance while removing metabolic waste from the brain. Neuronal electrical signal transmission requires correct ion levels while the brain's functionality depends on the removal of metabolic waste.
ABC Transporters
The ABCB1 (P-gp) transporter mediates the expulsion of drugs and toxic substances. The brain's ability to receive drugs is restricted by ABCB1 (P-gp), creating obstacles for treating central nervous system diseases.
Changes in the Blood - Brain Barrier in Diseases
The Blood-Brain Barrier loses its protective function under certain disease conditions. In Alzheimer's disease the glucose transporters malfunction which results in inadequate glucose delivery to the brain. This can further exacerbate the neurodegenerative process. The breakdown of the BBB permits harmful substances to gather in the brain while also blocking therapeutic drugs from reaching their targets which leads to disease progression.
Solute Carrier (SLC) Family
Drug uptake is primarily handled by the SLC family of transporters. The mechanism allows drug transport across cellular barriers through ion concentration gradients and facilitated diffusion processes. The sub-families organic anion transporting polypeptides (OATP), organic anion transporters (OAT), and organic cation transporters (OCT) enable cells to absorb different substances such as nutrients, hormones, and drugs.
ATP - Binding Cassette (ABC) Family
The ABC family acts primarily as the transport system responsible for moving drugs out of cells. The ATP hydrolysis process energizes the mechanism that expels drugs from cells. Representative transporters of this family include P-glycoprotein along with multi-drug resistance associated proteins and breast cancer resistance protein. The effectiveness and absorption of medications can be heavily influenced by these transporters.
Substrate Specificity
SLC family transporters function as the primary mediators for absorbing both natural metabolites from within the body and foreign substances that enter the organism. These transporters accommodate numerous substrates and depend on electrochemical or ion gradients to facilitate transport. ABC family transporters utilize ATP hydrolysis to move substrates in opposition to their concentration gradient. These transporters show high substrate specificity because they can detect and attach to multiple structurally similar molecules.
Regulation
SLC family transporters show varied regulation through hormones, growth factors, small molecule signals along with pH shifts, temperature variations and ion concentration changes. The primary controls for ABC family transporters include the levels of ATP alongside substrate concentration and interactions with intracellular signaling molecules as well as drugs.
Prodrug Strategy
Drug absorption through SLC or ABC transporters can be improved by applying chemical modification methods. The combination of SLC substrates with nanoparticles leads to better drug targeting and increased absorption efficiency.
Dual - Transporter Targeting Strategy
Drug delivery can be optimized through the strategic design of drug combinations that utilize the properties of both SLC and ABC transporters.
Gene Editing Technology
The CRISPR/Cas9 method allows scientists to control SLC or ABC transporter expression levels which enhances drug delivery efficiency.
The blood-brain barrier serves as a complex structure that maintains brain safety and function through its sophisticated organization which combines structural elements with transporter systems. Drug treatments become less effective because the blood-brain barrier serves as a protective barrier. Research into transporter regulation stands as a crucial step toward developing novel treatment methods. The future study of SLC and ABC transporters will aim to develop precise transporter regulation methods to enhance drug delivery systems and improve central nervous system disease treatments.
The blood-brain barrier maintains selective permeability through its structure consisting of three barriers.
Key mechanism: Occludin and claudin maintain minimal permeability between endothelial cells as transporter distribution facilitates accurate two-way substance control through P-glycoprotein toxin removal and GLUT1 glucose uptake.
Transporters are divided into two major categories:
Challenges: Multidrug resistance results from ABC transporter overexpression which affects treatments such as temozolomide for glioblastoma while the brain's drug concentration remains low due to SLC transporter uptake inefficiencies. New approaches involving nanocarriers which target P-selectin and gene editing which manages transporter expression show promise in addressing these challenges.
New discovery: Mutations in SLC19A3 cause rare diseases like thiamine deficiency encephalopathy because this gene transports vitamin B1 across the brain resulting in disrupted energy metabolism.
Clinical progress: Clinical trials for Spherical nucleic acid drugs (SNA) entered Phase II after demonstrating BBB penetration and Bcl2L12 oncogene suppression in glioblastoma patients.
References
| Target | Cat. No. | Product Name | Type | Host | Conjugate | Application | |
| Tryptophan | DAG155S | Tryptophan [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Trimethoprim | DAG156S | Trimethoprim [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Trimellitic anhydride | DAG157S | Trimellitic anhydride [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tobramycin | DAG158S | Tobramycin [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Thyroxine | DAG159S | Thyroxine [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Theophylline | DAG160S | Theophylline [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tetracycline | DAG161S | Tetracycline [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tetracaine | DAG162S | Tetracaine [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tenoxicam | DAG164S | Tenoxicam [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Tartrazine | DAG165S | Tartrazine [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Suxamethonium | DAG166S | Suxamethonium [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sunset Yellow FCF | DAG167S | Sunset Yellow FCF [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sulindac | DAG168S | Sulindac [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Streptomycin | DAG170S | Streptomycin [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Spiramycin | DAG171S | Spiramycin [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sorbic acid | DAG172S | Sorbic acid [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sodium sulfite | DAG173S | Sodium sulfite [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sodium nitrite | DAG174S | Sodium nitrite [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Sodium bisulfite | DAG175S | Sodium bisulfite [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
| Simvastatin | DAG176S | Simvastatin [HSA] | Synthetic | N/A | HSA | ELISA | Inquiry |
Loading ......
